Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Operating Leases (2022 - 2025)

Historic Operating Leases for Ovid Therapeutics (OVID) over the last 4 years, with Q3 2025 value amounting to $12.4 million.

  • Ovid Therapeutics' Operating Leases fell 1023.11% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year decrease of 1023.11%. This contributed to the annual value of $13.4 million for FY2024, which is 906.07% down from last year.
  • According to the latest figures from Q3 2025, Ovid Therapeutics' Operating Leases is $12.4 million, which was down 1023.11% from $12.7 million recorded in Q2 2025.
  • Ovid Therapeutics' 5-year Operating Leases high stood at $16.2 million for Q3 2022, and its period low was $12.4 million during Q3 2025.
  • For the 4-year period, Ovid Therapeutics' Operating Leases averaged around $14.6 million, with its median value being $14.8 million (2023).
  • Its Operating Leases has fluctuated over the past 5 years, first plummeted by 109.48% in 2023, then plummeted by 1023.11% in 2025.
  • Ovid Therapeutics' Operating Leases (Quarter) stood at $16.0 million in 2022, then fell by 7.78% to $14.8 million in 2023, then fell by 9.06% to $13.4 million in 2024, then dropped by 7.94% to $12.4 million in 2025.
  • Its last three reported values are $12.4 million in Q3 2025, $12.7 million for Q2 2025, and $13.1 million during Q1 2025.